This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


LFB Group

Drug Names(s): recombinant human antithrombin III, rhATIII, antithrombin alfa

Description: ATryn is recombinant human antithrombin, made from transgenic animals. Antithrombin is a human blood protein that has anticoagulant and anti-inflammatory properties.

Deal Structure: GTC Biotherapeutics and LEO Pharma
GTC Biotherapeutics and LEO Pharma A/S entered into a collaboration agreement in November 2005 to develop and market ATryn for markets in Europe, the Middle East, and Canada. The agreement includes $73 million in potential milestone payments to GTC for meeting regulatory, clinical and sales goals, with $2 million of this total paid upon signing of the agreement.

In January 2007, GTC Biotherapeutics transferred the market authorization of ATryn for the prophylaxis of venous thromboembolism to LEO Pharma, following approval by the European Commission. The transfer of the market authorization enables LEO to enter into negotiations of reimbursement rates as part of commercial launch preparations in Europe on a country-by-country basis.

In March 2009, GTC Biotherapeutics has notified LEO Pharma A/S that GTC is terminating their contract for commercialization and development of ATryn in the territories of Europe, Canada and the...See full deal structure in Biomedtracker

Partners: H. Lundbeck A/S Shin Poong Pharmaceutical Co., Ltd. Knight Therapeutics Inc.

ATryn News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug